Students and employees are being increasingly pressured to “just get the shot.” But since you choose to take these investigational products at your own risk, you might want to ask some questions.
Tuesday night April 27, 2021, on the Fox News Ingraham Angle, Dr. Peter McCullough gave his viewpoint that COVID-19 recovered patients do not have significant risks of clinical reinfection.
Dr. McCullough said natural immunity is far superior to that of the vaccine. There are already more than 7,000 breakthrough cases of COVID-19 in vaccinated persons, and very few have been reported and validated in someone who is naturally immune.
People who have recovered from COVID, however, have a higher risk of side effects, including a 50% higher incidence of severe side effects requiring hospital care.
Thus, Dr. McCullough said that he would not recommend administration of the COVID injections to these patients based on this risk-to-benefit ratio.
COVID survivors, pregnant women, and women of childbearing potential were excluded from randomized controlled trials (RCTs). So, there are NO published RCTs showing either safety or efficacy of the Pfizer, Moderna, or Johnson & Johnson products in these groups.
Current experience shows NO benefit, ONLY RISK.
At the present time, none of these products are FDA approved but are being given under an Emergency Use Authorization (EUA). Recipients are supposed to be notified of this fact and told that acceptance is voluntary. The consent form indicates that vaccination is voluntary, long-term effects (more than 2 months) are unknown, and side-effects can range from a painful swollen arm to death.
In response to the question of how it could require vaccines that aren’t FDA approved, the University of Colorado replied: “We anticipate FDA approval in the near future.” This would be unprecedented speed because there has not been adequate time for long-term adverse effects to manifest, and the accumulating safety data would preclude full approval.
Although people may assume that mandates are to protect against transmission, the trials were not designed to check for this, but only for the development of symptoms in the person vaccinated. There is no evidence that the vaccine could prevent you from transmitting the virus to others.
CU offered no rationale for requiring vaccination of staff who only work remotely.
For further information, see letter from the Association of American Physicians and Surgeons (AAPS) to university officials, urging them to respect the principles of autonomy and informed consent.
